Table 2.
Response to treatment with bosutinib and imatinib in the randomized trial for first-line treatment of chronic phase chronic myeloid leukemia.
Response | Bosutinib |
Imatinib |
||
---|---|---|---|---|
% | Time to response | % | Time to response | |
CCyR | 70% | 12.9 weeks | 68% | 24.6 weeks |
MMR | 41% | 37.1 weeks | 27% | 72.3 weeks |
CCyR, complete cytogenetic remission; MMR, major molecular remission.